3 recruiting, 2 not yet recruiting, 2 terminated, 1 active not recruiting. 6 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Not yet recruiting 2, Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1 |
| Phase 1 | 5 | Recruiting 3, Terminated 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Compass Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms CTX-471 - Neuroendocrine Neoplasm, Neuroendocrine Carcinomas | Phase 2 | Not yet recruiting | Compass Therapeutics | 58 | 2026-09-01 | 2026-07-06 |
| Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer Tovecimig, Irinotecan, Leucovorin - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 25 | 2026-08-31 | 2026-06-23 |
| Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma CTX-009, CTX-471 - Glioblastoma | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 54 | 2026-06-16 | 2026-06-22 |
| A Phase 1 Study of the Safety and Tolerability of CTX-10726 CTX-10726 - Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC) | Phase 1 | Recruiting | Compass Therapeutics | 70 | 2026-05-28 | 2026-10-02 |
| A Phase 1 of CTX-8371 in Patients With Advanced Malignancies CTX-8371 - Non Small Cell Lung Cancer, Triple Negative Breast Cancer | Phase 1 | Recruiting | Compass Therapeutics | 85 | 2024-03-19 | 2026-07-28 |
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) CTX-009, Paclitaxel - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Compass Therapeutics | 168 | 2023-01-09 | 2026-09-02 |
| A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer CTX-009 - Metastatic Colorectal Cancer, Colon Cancer | Phase 2 | Completed | Compass Therapeutics | 49 | 2022-12-08 | 2026-09-25 |
| A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients CTX-009 (ABL001), Paclitaxel, Irinotecan - P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | Handok Inc. | 41 | 2020-06-22 | 2025-01-27 |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies CTX-471, Pembrolizumab (KEYTRUDA®) - Locally Advanced Solid Tumor, Metastatic Cancer | Phase 1 | Terminated | Compass Therapeutics | 100 | 2019-05-17 | 2026-10-09 |
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Melanoma (2) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Glioblastoma (1) · Head and Neck Neoplasms (1) · Hodgkin Disease (1) · Mesothelioma (1)
Irinotecan (2) · Paclitaxel (2) · Fluorouracil (1) · Leucovorin (1) · asciminib (1) · pembrolizumab (1)
United States (7) · South Korea (1)
Cynthia Sirard, MD (2) · Minori Rosales, MD, PhD (1) · Olivia Aranha, MD, PhD (1) · Tanner M Johanns, MD, PhD (1) · Thomas Scheutz, MD, PhD (1)